Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $27000.0.

  • Dianthus Therapeutics' Depreciation & Amortization (CF) rose 800.0% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $110000.0, marking a year-over-year increase of 2222.22%. This contributed to the annual value of $96000.0 for FY2024, which is 4328.36% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Depreciation & Amortization (CF) of $27000.0 as of Q3 2025, which was up 800.0% from $30000.0 recorded in Q2 2025.
  • Dianthus Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $511000.0 during Q1 2022, with a 5-year trough of $19000.0 in Q3 2023.
  • In the last 4 years, Dianthus Therapeutics' Depreciation & Amortization (CF) had a median value of $27000.0 in 2025 and averaged $183214.3.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 9596.6% in 2023, then soared by 3157.89% in 2024.
  • Dianthus Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $466000.0 in 2022, then plummeted by 95.71% to $20000.0 in 2023, then increased by 30.0% to $26000.0 in 2024, then increased by 3.85% to $27000.0 in 2025.
  • Its last three reported values are $27000.0 in Q3 2025, $30000.0 for Q2 2025, and $27000.0 during Q1 2025.